DE69326388D1 - Verfahren zur Herstellung von Staurosporin-Derivaten - Google Patents

Verfahren zur Herstellung von Staurosporin-Derivaten

Info

Publication number
DE69326388D1
DE69326388D1 DE69326388T DE69326388T DE69326388D1 DE 69326388 D1 DE69326388 D1 DE 69326388D1 DE 69326388 T DE69326388 T DE 69326388T DE 69326388 T DE69326388 T DE 69326388T DE 69326388 D1 DE69326388 D1 DE 69326388D1
Authority
DE
Germany
Prior art keywords
preparation
staurosporine derivatives
staurosporine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69326388T
Other languages
English (en)
Other versions
DE69326388T2 (de
Inventor
Chikara Murakata
Toshimitsu Takiguchi
Shigeo Katsumata
Akira Mihara
Keiichi Takahashi
Hiromitsu Saito
Shiro Akinaga
Masami Okabe
Yutaka Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP04162813A external-priority patent/JP3112343B2/ja
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE69326388D1 publication Critical patent/DE69326388D1/de
Publication of DE69326388T2 publication Critical patent/DE69326388T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69326388T 1992-06-22 1993-06-22 Verfahren zur Herstellung von Staurosporin-Derivaten Expired - Fee Related DE69326388T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16281492 1992-06-22
JP04162813A JP3112343B2 (ja) 1992-06-22 1992-06-22 Ｕｃｎ−０１の製造法

Publications (2)

Publication Number Publication Date
DE69326388D1 true DE69326388D1 (de) 1999-10-21
DE69326388T2 DE69326388T2 (de) 1999-12-30

Family

ID=26488474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326388T Expired - Fee Related DE69326388T2 (de) 1992-06-22 1993-06-22 Verfahren zur Herstellung von Staurosporin-Derivaten

Country Status (4)

Country Link
US (1) US5344926A (de)
EP (1) EP0575955B1 (de)
DE (1) DE69326388T2 (de)
ES (1) ES2136103T3 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE69331228D1 (en) * 1992-09-21 2002-01-10 Kyowa Hakko Kogyo Kk Heilmittel für thrombozytopenia
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994020106A1 (en) * 1993-03-03 1994-09-15 Kyowa Hakko Kogyo Co., Ltd. Sensitivity enhancer for antineoplastic agent
PH30300A (en) * 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
US5604219A (en) * 1994-03-18 1997-02-18 Kyowa Hakko Kogyo Co., Ltd. Indolocarbazole derivatives that stimulate platelet production
EP0717045B1 (de) * 1994-07-04 2001-04-04 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur herstellung von indolocarbazol-derivaten
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
BR9710693A (pt) 1996-06-25 2000-01-11 Cephalon Inc Uso de um derivado de k-252a para o tratamento do nervo central ou periférico e super produção de citoquinona.
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
JP2000186092A (ja) * 1998-12-22 2000-07-04 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１の製造法
ES2155379B1 (es) * 1999-04-05 2001-12-01 Univ Cantabria Procedimiento para producir plaquetas humanas a partir de celulas en cultivo.
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
CN101703509A (zh) 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
WO2004030622A2 (en) 2002-09-30 2004-04-15 Auburn University Method of isolation and self-assembly of small protein particles from blood and other biological materials
DE60305634T2 (de) * 2003-03-07 2006-09-21 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Anaplastisches Lymphoma Kinase Testverfahren, Reagenzien und Kompositionen davon
WO2004094645A1 (en) * 2003-04-22 2004-11-04 Lonza Ag Process for the recovery of staurosporine from a fermentation broth
MXPA06001524A (es) 2003-08-08 2006-05-15 Novartis Ag Combinaciones que comprenden estaurosporinas.
JO2897B1 (en) 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
BR112015013715A2 (pt) 2012-12-12 2017-09-26 Promega Corp sistema, método para capturar o alvo celular, lisado celular e ligante de captura.
US10168323B2 (en) 2013-03-15 2019-01-01 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
TWI538914B (zh) * 2014-10-03 2016-06-21 國立交通大學 蛋白質激酶之選擇性抑制劑、其醫藥組成物及其用途
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (ja) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
EP0383919A4 (en) * 1988-02-04 1992-08-05 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
US5015578A (en) * 1989-03-23 1991-05-14 Bristol-Myers Squibb Company BMY-41950 antitumor antibiotic
AU7035991A (en) * 1989-12-14 1991-07-18 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
US4973552A (en) * 1990-02-20 1990-11-27 Bristol-Meyers Squibb Company Staurosporine fermentation process
MX9201643A (es) * 1991-04-11 1992-10-01 Schering Corp Agentes contra tumores y anti-psoriasicos.

Also Published As

Publication number Publication date
ES2136103T3 (es) 1999-11-16
DE69326388T2 (de) 1999-12-30
EP0575955B1 (de) 1999-09-15
US5344926A (en) 1994-09-06
EP0575955A1 (de) 1993-12-29

Similar Documents

Publication Publication Date Title
DE69326388T2 (de) Verfahren zur Herstellung von Staurosporin-Derivaten
DE59108200D1 (de) Verfahren zur Herstellung von Nitroguanidinderivaten
DE59303220D1 (de) Verfahren zur Herstellung von 1-Fluorcyclopropyl-methyl-keton
DE69324118T2 (de) Verfahren zur Herstellung von Riboflavin
ATA206691A (de) Verfahren zur herstellung von 8-chlorochinolonderivaten
DE69314899T2 (de) Verfahren zur Herstellung von Polyaminoborazinen
DE69315297T2 (de) Verfahren zur Herstellung von Omega-Alkenylchlorsilanen
DE69118001T2 (de) Verfahren zur Herstellung von beta-Lactamderivaten
DE69303057D1 (de) Verfahren zur Herstellung von 3-Cyano-6-hydroxypyridin
DE69216125D1 (de) Verfahren zur Herstellung von 2-Exo-methylenpenam-Derivaten
DE69431537T2 (de) Verfahren zur Herstellung von 5-Trifluormethyluracil-Derivaten
DE69315317T2 (de) Verfahren zur Herstellung von beta-Cyanoalkylsilanen
DE69323598T2 (de) Verfahren zur Herstellung von Cyclopentadienderivate
DE59405997D1 (de) Verfahren zur Herstellung von Hydroxyalkylaminonitrobenzol-Derivaten
DE69200795T2 (de) Verfahren zur Herstellung von L-Prolinederivaten.
DE69305279D1 (de) Verfahren zur Herstellung von Dimethyltetralin
DE59306959D1 (de) Verfahren zur Herstellung von Difluor- und Chlorfluorbenzodioxolen
DE69308193T2 (de) Verfahren zur Herstellung von Alpha-L-Aspartyl-L-Phenylalanin
DE69319683D1 (de) Verfahren zur Herstellung von Thienothiopyran-Derivaten
DE69304839T2 (de) Verfahren zur Herstellung von Nukleosidderivaten
DE59208718D1 (de) Verfahren zur Herstellung von Imidazothiazolon-Derivaten
DE69315007D1 (de) Verfahren zur Herstellung von Carbapenem-Derivaten
DE69218729T2 (de) Verfahren zur Herstellung von (+)-Estronderivaten
DE59304663D1 (de) Verfahren zur Herstellung von 4-Hydroxymethyltetrahydropyran
DE69303656T2 (de) Verfahren zur Herstellung von 2-Oxytetrahydrofurane

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: DERZEIT KEIN VERTRETER BESTELLT

8339 Ceased/non-payment of the annual fee